POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a clinical-stage radiopharmaceutical company focused on developing and manufacturing targeted radioligand therapies for oncology. The company completed its business combination with GX Acquisition Corp. II, sponsored by GX Sponsor II LLC, in mid-2021, with the transaction closing reflected in an 8-K filing dated June 30, 2021. GX Acquisition Corp. II completed its IPO in 2020, targeting the healthcare and life sciences sector. Following the de-SPAC, POINT Biopharma traded on Nasdaq under the ticker PNT, advancing a pipeline of radiopharmaceutical candidates aimed at treating solid tumors. For complete filing history, deal terms, and sponsor data on PNT and hundreds of other SPACs, sign up for full access at SpacDesk.